This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Tiziana Life Sciences Chair Boosts Stake as Foralumab Trials Advance

Tipranks - Tipranks - Tue Jun 16, 6:36AM CDT

Claim 55% Off TipRanks

The latest announcement is out from Tiziana Life Sciences ( (TLSA) ).

On June 15, 2026, Tiziana Life Sciences announced that Executive Chairman and founder Gabriele Cerrone, via Panetta Partners, increased his stake in the company by purchasing 15,000 common shares at $1.11 apiece. The transaction lifts his total holding to 44,772,230 shares, representing 34.89% of Tiziana’s issued share capital and further aligns the chairman’s interests with those of other investors.

The move comes as Tiziana advances intranasal foralumab through clinical development, including an expanded access program and an ongoing Phase 2a trial in non-active secondary progressive multiple sclerosis. Cerrone’s larger position underscores insider confidence in the company’s patented intranasal immunotherapy platform, which aims to improve efficacy, safety, and tolerability versus traditional intravenous delivery and could strengthen Tiziana’s standing in the neuroimmunology space.

The most recent analyst rating on (TLSA) stock is a Buy
with a $8.00 price target.
To see the full list of analyst forecasts on Tiziana Life Sciences stock,
see the TLSA Stock Forecast page.

More about Tiziana Life Sciences

Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on breakthrough immunomodulation therapies enabled by alternative drug delivery technologies. Its lead product candidate is intranasal foralumab, the only fully human anti-CD3 monoclonal antibody currently in clinical development, targeting neuroinflammatory and neurodegenerative conditions such as non-active secondary progressive multiple sclerosis.

Average Trading Volume: 205,981

Technical Sentiment Signal: Sell

Current Market Cap: $130.7M

See more insights into TLSA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).